eli lilly sleep apnea news

obstructive sleep apnea, FDA and obesity

FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

The Wall Street Journal on MSN · 5d

Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.

Hosted on MSN · 3d

FDA approves first medication for obstructive sleep apnea, which also promotes weight loss

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.

USA Today7d

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication ...

SchaeffersResearch.com5d

2 Sleep Apnea Stocks in Focus Today

Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity ...

NBC New York7d

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

Eli Lilly expects to launch the drug for OSA at ... The index is used to evaluate the severity of obstructive sleep apnea and the effectiveness of treatments for the condition.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

obstructive sleep apnea, FDA and obesity

Trending now